HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.

Abstract
Icofungipen (PLD-118) is the representative of a novel class of antifungals, beta amino acids, active against Candida species. It has been taken through phase II clinical trials. The compound actively accumulates in yeast, competitively inhibiting isoleucyl-tRNA synthetase and consequently disrupting protein biosynthesis. As a result, in vitro activity can be studied only in chemically defined growth media without free amino acids that would compete with the uptake of the compound. The MIC of icofungipen was reproducibly measured in a microdilution assay using yeast nitrogen base medium at pH 6 to 7 after 24 h of incubation at 30 to 37 degrees C using an inoculum of 50 to 100 CFU/well. The MICs for 69 Candida albicans strains ranged from 4 to 32 microg/ml. This modest in vitro activity contrasts with the strong in vivo efficacy in C. albicans infection. This was demonstrated in a lethal model of C. albicans infection in mice and rats in which icofungipen showed dose-dependent protection at oral doses of 10 to 20 mg/kg of body weight per day in mice and 2 to 10 mg/kg/day in rats. The in vivo efficacy was also demonstrated against C. albicans isolates with low susceptibility to fluconazole, indicating activity against azole-resistant strains. The efficacy of icofungipen in mice and rats was not influenced by concomitant administration of equimolar amounts of L-isoleucine, which was shown to antagonize its antifungal activity in vitro. Icofungipen shows nearly complete oral bioavailability in a variety of species, and its in vivo efficacy indicates its potential for the oral treatment of yeast infections.
AuthorsAndreja Hasenoehrl, Tatjana Galic, Gabrijela Ergovic, Natasa Marsic, Mihael Skerlev, Joachim Mittendorf, Ulrich Geschke, Axel Schmidt, Wolfgang Schoenfeld
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 50 Issue 9 Pg. 3011-8 (Sep 2006) ISSN: 0066-4804 [Print] United States
PMID16940096 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antifungal Agents
  • Isoleucine
  • Cycloleucine
  • 2-amino-4-methylenecyclopentane-1-carboxylic acid
Topics
  • Animals
  • Antifungal Agents (pharmacology)
  • Candida albicans (drug effects, isolation & purification, pathogenicity)
  • Candidiasis (drug therapy)
  • Cycloleucine (analogs & derivatives, antagonists & inhibitors, pharmacology)
  • Drug Interactions
  • Hydrogen-Ion Concentration
  • Isoleucine (pharmacology)
  • Male
  • Mice
  • Microbial Sensitivity Tests
  • Rats
  • Rats, Sprague-Dawley
  • Temperature

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: